New frontiers in pediatric Allo-SCT.

New frontiers in pediatric Allo-SCT.
复制标题

DOI:
10.1038/bmt.2014.89
复制
发表时间:
2014-09
影响因子:
4.8
通讯作者:
Cairo, M. S.
Cairo, M. S.
中科院分区:
医学3区
文献类型:
--
作者:
Talano, J. M.;Pulsipher, M. A.;Symons, H. J.;Militano, O.;Shereck, E. B.;Giller, R. H.;Hancock, L.;Morris, E.;Cairo, M. S.

文献摘要

参考文献

相似文献

由儿科血液和移植联盟(PBMTC)组织的“儿科异基因干细胞移植新前沿”成立大会在美国儿科血液学和肿瘤学学会年会上举行。本次会议为积极参与儿科异基因干细胞移植(AlloSCT)在患有恶性和非恶性疾病的儿童和青少年中的研究和利用的医生和研究人员提供了一个国际平台,以分享信息并制定未来的合作策略。会议的主要目的包括:1)介绍AlloSCT在儿童ALL中的进展以及新型免疫治疗前和免疫治疗后; 2)强调非恶性血液病儿童和青少年替代异基因干细胞供体来源的新策略; 3)讨论AlloSCT后免疫重建的时机以及促进免疫力更快恢复的方法; 4)确定在儿科骨髓增生性疾病(MPD)中利用AlloSCT的策略; 5)开发儿科AlloSCT后血液学并发症的诊断和治疗方法; 6)增强对儿科恶性和非恶性血液学疾病的新的新颖细胞治疗方法的理解; 7)探讨儿童AlloSCT受者的最佳药物治疗。本文将简要介绍会议概况。
The inaugural meeting of “New Frontiers in Pediatric Allogeneic Stem Cell Transplantation” organized by the Pediatric Blood and Transplant Consortium (PBMTC) was held at the American Society of Pediatric Hematology and Oncology Annual Meeting. This meeting provided an international platform for physicians and investigators active in the research and utilization of pediatric allogeneic stem cell transplantation (AlloSCT) in children and adolescents with malignant and non-malignant disease, to share information and develop future collaborative strategies. The primary objectives of the conference included: 1) to present advances in AlloSCT in pediatric ALL and novel pre- and post-immunotherapy; 2) to highlight new strategies in alternative allogeneic stem cell donor sources for children and adolescents with non-malignant hematological disorders; 3) to discuss timing of immune reconstitution after AlloSCT and methods of facilitating more rapid recovery of immunity; 4) to identify strategies of utilizing AlloSCT in pediatric myeloproliferative disorders (MPD); 5) to develop diagnostic and therapeutic approaches to hematological complications post pediatric AlloSCT; 6) to enhance the understanding of new novel cellular therapeutic approaches to pediatric malignant and non-malignant hematological disorders; and 7) to discuss optimizing drug therapy in pediatric recipients of AlloSCT. This paper will provide a brief overview of the conference.
DOI: 10.1200/jco.2004.05.198
发表时间: 2004-05-01
影响因子: 45.3
作者:
Bader, P;Kreyenberg, H;Klingebiel, T
通讯作者: Klingebiel, T
DOI: 10.1038/sj.bmt.1704198
发表时间: 2003-09-01
影响因子: 4.8
作者:
Bunin, N;Aplenc, R;Simms, S
通讯作者: Simms, S
DOI: 10.1182/blood-2011-06-362111
发表时间: 2011-11-24
期刊: BLOOD
影响因子: 20.3
作者:
Ciurea, Stefan O.;Thall, Peter F.;Fernandez-Vina, Marcelo
通讯作者: Fernandez-Vina, Marcelo
DOI: 10.1182/blood-2012-03-417758
发表时间: 2012-10-04
期刊: BLOOD
影响因子: 20.3
作者:
Horan, John;Wang, Tao;Woolfrey, Ann
通讯作者: Woolfrey, Ann